Browse the corpus

This program focuses on the role of abacavir, a nucleoside reverse transcriptase inhibitor, in treating human immunodeficiency virus 1 (HIV-1) infection when combined with other antiretroviral agents. This course explores the indications, dosing schedules, contraindications, and potential adverse effects of abacavir use. Antiretroviral therapy is a critical factor in achieving favorable outcomes for HIV patients, and this program places a significant emphasis on the importance of treatment adherence and the prevention of drug resistance. This course highlights the crucial role of an interprofessional healthcare team in caring for individuals with HIV. By integrating the expertise and perspectives of various healthcare professionals, this program ensures a comprehensive approach to patient care, ultimately leading to optimal treatment strategies and improved patient outcomes. Participants will gain valuable insights and tools to manage HIV effectively, reduce the risk of drug resistance, and enhance treatment adherence, contributing to the overall success of antiretroviral therapy. Objectives: Identify patients who require antiretroviral therapy, including abacavir, for managing HIV-1 based on clinical guidelines and diagnostic criteria. Implement and integrate abacavir into antiretroviral regimens efficiently, adhering to prescribed dosages and appropriate combinations as per established HIV treatment protocols. Assess patient responses to abacavir therapy regularly, monitoring treatment adherence, viral load suppression, and potential drug-related complications through laboratory tests and clinical evaluations. Determine strategies with other healthcare team members to ensure seamless implementation, monitoring, and optimization of abacavir therapy within the broader context of HIV management. Access free multiple choice questions on this topic.

Severe and sometimes fatal hypersensitivity reactions can potentially occur with abacavir. Patients with the HLA-B*5701 allele also carry a higher risk for a hypersensitivity reaction to abacavir; hypersensitivity reactions have occurred in those who do not test positive for the HLA-B*5701 allele. All patients should receive screening for the HLA-B*5701 allele.[17]

Managing abacavir administration to HIV patients requires an interprofessional team of healthcare professionals that includes a nurse, laboratory technologists, pharmacists, social workers, and several physicians in different specialties. After HIV diagnosis, prompt admission into HIV medical and adherence/retention is fundamental to the administration of effective antiretroviral therapy. Adherence to antiretroviral therapy (ART) is one of the top factors of favorable HIV treatment outcomes and is necessary to decrease the occurrence of drug resistance within the patient. Common obstacles to successful ART stem from an absence of social support and alcohol or substance abuse, which prevent patients from having sustained therapy. The emphasis on adherence cannot be overstated. Physicians, advanced practice practitioners, specialists, nurses, and pharmacists must all share in the effort to educate the patient and monitor pharmacotherapy adherence. For example, if the patient is chronically late picking up their prescription, the pharmacist must call the physician's office and share this information with the nurse or prescriber. The pharmacist is also responsible for medication reconciliation and verifying dosing parameters. On follow-up visits, the nurse must verify adherence and should do so by asking open-ended questions that encourage the patient to reveal familiarity with their regimen. Failure to take the drugs in ART correctly can result in therapeutic failure for the entire drug class, as the virus can obtain adaptive drug resistance; any ART requires open, interprofessional team communication to ensure the best chance for therapeutic success. Recommendations for Increasing Successful Outcomes in Antiretroviral Therapy Initiation of highly active antiretroviral therapy (HAART) with a high degree of adherence, defined as greater than 95% refills and plasma drug concentrations above the therapeutic steady-state concentration, is associated with low levels of antiretroviral resistance.[21] Individual-level monitoring of entry and retention is a strong recommendation for all people diagnosed with HIV.[22][23] Systematic retention monitoring in HIV care is also strongly recommended for all HIV patients.[24] Strengths-based case management from trained social workers increases entry to HIV medical care.[25]

Initiation of highly active antiretroviral therapy (HAART) with a high degree of adherence, defined as greater than 95% refills and plasma drug concentrations above the therapeutic steady-state concentration, is associated with low levels of antiretroviral resistance.[21] Individual-level monitoring of entry and retention is a strong recommendation for all people diagnosed with HIV.[22][23] Systematic retention monitoring in HIV care is also strongly recommended for all HIV patients.[24] Strengths-based case management from trained social workers increases entry to HIV medical care.[25] Self-report adherence should be obtained routinely in all HIV patients.[26] Regimens of similar efficacy and tolerability, once-daily regimens are recommended in treatment-naïve patients starting ART and experienced patients receiving poorly tolerated/complex regimens.[26][27][28][29] Reminders and the use of communication technologies with an interactive component are recommended to increase adherence [30] Combining education and counseling using specific adherence-related tools is recommended for all patients with HIV.[31][32][33] Directly administered ART (DART) is the recommended course of action in individuals with substance use disorders.[34][35][36] Cognitive-behavioral therapy is recommended in patients with depression to improve adherence.[37]